Approbation of a New Pharmacological Assessment Model Activities of Enterosorbent in vivo on the Experimental Samples

The use of therapeutic and prophylactic drugs based on organosilicon sorbents promotes rapid recovery by normalizing intestinal microbiocenosis, suppressing lipid peroxidation, detoxification, activation of liver function and gentle healing of ulcers, early eradication of Helicobacter pylori. Also, the use of organosilicon sorbents reduces the toxic load, leads to natural detoxification, and leads to healing in erosive and ulcerative processes of the gastrointestinal tract, in contrast to adsorbents based on coal and clay. Based on the available data, a new approach to the pharmacological assessment of enterosorbent from the point of view of their specific action-adsorption activity-has been proposed using a test drug with previously described pharmacokinetics-lornoxicam-as an analyte. In view of the best compliance with the requirements for an “ideal” enterosorbent, several experimental samples of the sorbent were selected to test the method proposed in this work. Using High-performance liquid chromatography (HPLC) with tandem mass spectrometry (MS) on Chinchilla rabbits, the bioavailability of Lornoxicam, selected as a test drug, was studied when Lornoxicam and Lornoxicam were used together with selected enterosorbent. It has been established that the bioavailability of Lornoxicam with the simultaneous use of the studied enterosorbent decreases sharply. The data obtained make it possible to judge the adsorption activity of enterosorbent and evaluate it by changes in the relative bioavailability of the test drug. Thus, as a result of the conducted research, an original method for determining the adsorption activity of enterosorbent in vivo was proposed, which claims to be a new pharmacological model. © 2024 Elsevier B.V., All rights reserved.